Lyngby, Denmark

Tine Glendorf


 

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 13(Granted Patents)


Location History:

  • Lyngby, DK (2013 - 2019)
  • Hilleroed, DK (2022)

Company Filing History:


Years Active: 2013-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Tine Glendorf: Pioneering Innovations in Diabetes Treatment

Introduction:

Tine Glendorf is a visionary inventor based in Lyngby, Denmark, known for his groundbreaking work in the field of diabetes treatment. With a passion for innovation and a drive for excellence, he has left a lasting impact on the medical industry.

Latest Patents:

1. Insulin derivatives and the medical uses hereof: Tine Glendorf's invention focuses on novel acylated derivatives of human insulin analogues, offering new possibilities for the treatment and prevention of diabetes-related medical conditions.

2. Protease stabilized acylated insulin analogues: His innovative insulin analogues, containing specific elements like B25H and A14E or A14H, demonstrate increased resistance towards proteases, allowing for effective pulmonary or oral administration.

Career Highlights:

Tine Glendorf is a valued member of the renowned company Novo Nordisk A/S, a leader in the pharmaceutical industry. Through his expertise and dedication, he has contributed significantly to the advancement of diabetes treatment technologies.

Collaborations:

Within Novo Nordisk A/S, Tine Glendorf has collaborated closely with his esteemed coworkers Peter Madsen and Thomas Boerglum Kjeldsen. Together, they have pushed the boundaries of medical science and brought forth innovative solutions for patients worldwide.

Conclusion:

In conclusion, Tine Glendorf's pioneering spirit and commitment to excellence have paved the way for cutting-edge advancements in diabetes treatment. His inventions continue to inspire inventors and entrepreneurs, leaving a remarkable legacy in the world of innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…